Latest Breaking News On - All three dose levels - Page 1 : comparemela.com

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

/PRNewswire/ Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies.

United statesRodney varnerMark bergerAmerican society of clinical oncologyGenprex incPrnewswire genprex incCompany websiteExchange commissionDrug administrationResults show combinationWell toleratedAll three dose levelsEncouraging evidenceImmunogene therapyClinical oncologyAnnual meeting

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting

Genprex Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating REQORSA® Immunogene Therapy in Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKalyn dabbsRodney varnerMark bergerAmerican society of clinical oncologyDrug administrationPrnewswire genprex incExchange commissionCompany websiteGenprex incResults show combinationWell toleratedAll three dose levelsEncouraging evidenceImmunogene therapyClinical oncology